47.21MMarket Cap-599P/E (TTM)
2.8800High2.8800Low3.81KVolume2.8800Open2.8400Pre Close10.98KTurnover0.03%Turnover RatioLossP/E (Static)16.39MShares8.950052wk High2.60P/B41.91MFloat Cap2.610052wk Low--Dividend TTM14.55MShs Float242.0000Historical High--Div YieldTTM0.00%Amplitude2.2350Historical Low2.8800Avg Price1Lot Size
Affimed NV Stock Forum
Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
-- LuminICE-203: Efficacy update of cohorts 1-4 expected to be presented at
a future scientific conference in Q4 2024.
-- AFM24-102: ORR and safety data from the EGFRwt cohort in Q4 2024.
-- AFM28-101: Data from the study is expected to be presented at a
scientific conference in Q4 2024.
-- AMF24-102: Mature PFS data from EGFRmut and EGFRwt cohorts expected to be
presented at a future conference in H1...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
• ORR and PFS data from the 25 patients in the EGFRmut cohort of the AFM24-102 study in Q3 2024.
• ORR and PFS data from the 40 patients in the EGFRwt cohort of the AFM24-102 study in Q4 2024.
On fire
Larger Image: tradingview.com...
$Affimed NV (AFMD.US)$
👉 GHOST NET - DEMON TRAP - GAI WIX 👈👉 BUYERS MUST SELL ALL AND DELETE NOW👈. 👎THEY BLOCK SHORT + (BID & ASK TOO FAR & UNDER $1 DELETE ), THEY ONLY TRAP STUPID INVESTORS BILLION OF DOLLARS A DAY 🗡👊💣👹💰
(STOK - PIK - LPA - DHAC - SMFL - SMMT - SRDX - VSTM - SMR - UVXY - AVTX - BTTR - DXYZ - GNLX - CZOO - MRUS - OKLO - AKAN - SWIN - IGMS - ARRY - MARA - CTNT - GTBP - EDBL - MTC - CAR - ARM - CVNA - SITM - NSP - POWL - AWIN - BIG - BMTX - DXYZ - DOGZ - HOLO - KOSS - MGNX - TTO...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort
Affimed has announced promising follow-up data for its AFM24 and atezolizumab combination therapy in heavily pretreated non-small cell lung cancer (NSCLC) patients. In the EGFR wild-type (EGFRwt) cohort, 4 out of 15 response-evaluable patients showed objective responses, with ...
No comment yet